NCCN Flash Updates: NCCN Guidelines and NCCN Templates Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines^® are currently available as Version 4.2021.

Link directly to the Updates section of the NCCN Guidelines: 
Acute Lymphoblastic Leukemia

• The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

NCCN has published updates to the NCCN Guidelines for Prostate Cancer. These NCCN Guidelines are currently available as Version 3.2022. 

Link directly to the Updates section of the NCCN Guidelines: 
Prostate Cancer

• The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Malignant Pleural Mesothelioma to reflect the currently published NCCN Guidelines for Malignant Pleural Mesothelioma v1.2022.

• Changes to the Indication section have been made on the following NCCN Templates^®:
  • MPM1: PEMEtrexed/CISplatin
  • MPM2: PEMEtrexed/CARBOplatin
  • MPM7: PEMEtrexed/CISplatin + Bevacizumab followed by Bevacizumab Maintenance
  • MPM8: PEMEtrexed/CARBOplatin + Bevacizumab followed by Bevacizumab Maintenance
  • MPM11: Nivolumab + Ipilimumab
• References have been updated on the following templates:
  • MPM10: Nivolumab
  • MPM11: Nivolumab + Ipilimumab
• Changes to the Chemotherapy Regimen section have been made on the following templates:
  • MPM1: PEMEtrexed/CISplatin
  • MPM2: PEMEtrexed/CARBOplatin
  • MPM11: Nivolumab + Ipilimumab
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Ipilimumab
  • Nivolumab
  • VinORELBine

NCCN has published updates to the NCCN Templates for Thymomas and Thymic Carcinomas to reflect the currently published NCCN Guidelines for Thymomas and Thymic Carcinomas v1.2022.

• Changes to the Indication section have been made on the following NCCN Templates:
  • THYM9: Octreotide and Octreotide LAR/PredniSONE
  • THYM15: Octreotide and Octreotide LAR
• Changes to the Chemotherapy Regimen section have been made on the following template:
  • THYM17: Everolimus
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Capecitabine
  • DOXOrubicin
  • Ifosfamide
  • Lenvatinib
  • Octreotide LAR
  • Pembrolizumab
  • SUNItinib
  • VinCRIStine

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please  note:  1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.